Hypoglycemia: While GLP-1 medications themselves rarely cause hypoglycemia (low blood sugar) when used as monotherapy, combining them with a mechanism of action that causes hypoglycemia such as insulin or sulfonylureas can increase the risk of hypoglycemia
Instead of blocking the signaling proteins, bima works by blocking the receptor for myostatin, activin A, and other body-composition regulating signals
doi:10.1038/ijo.2015.59 Jensen SBK, Blond MB, Sandsdal RM, et al
The Ozempic MDL added 73 cases between May and June, bringing the total to 1,882
For prior authorization to be approved for a GLP-1 medication, we will need to provide specific information about your medical condition and treatment history